All News

Despite the growing availability of prescription digital therapeutics (PDTs) coming to market, few products have gone through rigorous standards of evidence testing, according to one study.

Rhenium (186Re) obisbemeda (Plus Therapeutics) shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be evaluated in the ReSPECT-LM program. The orphan drug designation (ODD) was granted on November 3.

Intravitreal aflibercept was used in patients with retinal vein occlusion (RVO) which led to functional and anatomic improvements in the patients after treatment.

Phathom Pharmaceuticals' vonoprazan (Voquenza) sets a new standard in erosive gastroesophageal reflux disease (GERD) therapy.

CDC plans to monitor over 30 pathogens in high-risk airports; a surge in ketamine prescriptions raises questions about safety and oversight; changes to come in Affordable Care Act (ACA) enrollment for 2023.

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant consideration of pharmacotherapy, and 1 in 48 had high levels of LDL-C that are indicated for medication.

The prevalence of eosinophilic asthma and severe asthma phenotypes was high in many countries, according to one study.

Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.

Presenters at American Society of Nephrology Kidney Week 2023 highlighted the importance of understanding the barriers faced by the LGBTQ+ community that impact kidney outcomes and the need to gather better data for studying these issues.

The distribution of eyebrow and eyelash hair loss in relation to the severity of scalp hair loss remains underexplored, and this study established baseline characteristics.

Presenters at the American Society of Nephrology (ASN) Kidney Week 2023 highlighted the exciting new technologies that nephrology research has developed to improve patient outcomes, quality of life, and approaches to care.

Data from 2176 US counties link obesity and higher breast cancer mortality, while also showing varying degrees of association between mortality and access to healthy lifestyle options per social determinants of health (SDOH).

Natural infection plus COVID-19 vaccination in pregnant mothers conferred more durable antibody responses in infants than natural infection alone.

This newly developed prediction model evaluating community-acquired pneumonia risk was noted to demonstrate accuracy, strong discriminatory qualities, and practicability in clinical settings.

Mothers in the United States were surveyed about the time of disclosure of their HIV status to their children, with internalized stigma of HIV a significantly associated factor.

Posters at ASN Kidney Week 2023 explored the economic burden brought on by chronic kidney disease (CKD) and further validated the Klinrisk model’s ability to predict progressive forms of CKD.

The use of a bioartificial kidney could save the transplant population from a life of immunosuppression drugs and save costs, according to Shuvo Roy, PhD, professor of bioengineering at the University of California San Francisco.

A child with profound genetic hearing loss was dosed with the investigational otoferlin gene therapy (DB-OTO), becoming the first patient dosed in a phase 1/2 trial evaluating the treatment, and experienced improved auditory response at week 6 with no concerning safety signals.

The Enhancing Oncology Model is trying to address a number of the systemic challenges oncology faces without giving practices the tools and resources they need, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.

A study showed the Clostridioides difficile infection (CDI) treatment remained effective after subsequent systemic antibiotic exposure.

Patients with paroxysmal nocturnal hemoglobinuria (PNH) who had suboptimal response to eculizumab can switch to pegcetacoplan for a cost-effective alternative, according to. acost analysis.

Presenters at ASN Kidney Week 2023 emphasized the importance of patient education, awareness, and advocacy in the realm of kidney transplantation.

A retrospective study presented at the 2023 American Association of Neuromuscular and Electrodiagnotsic Medicine meeting revealed that social determinants of health (SDOH) are linked to poorer treatment outcomes in patients who have myasthenia gravis, emphasizing the need for identifying and supporting at-risk individuals.

Poor sleep and insomnia symptoms were both associated with an increased likelihood of elevated emotional exhaustion among emergency health care workers.

Because of their study's findings, the researchers urged clinicians to screen patients with atopic dermatitis (AD) for cognitive dysfunction.

Changes in the medication therapy management (MTM) program willl require planning on how to best fund this program in a way that drives medical cost savings.

“Our findings further reinforce that place is important and that the social, economic, and health care equity context is key to minimizing health care expenditure disparities for Black adults in the US," investigators explain.

Many sleep experts want to permanently stay in the standard time zone; Medicare will cover mental health counselors and marriage and family therapists beginning in January; a new Minnesota law requires hospitals to check if patients are eligible for financial assistance before referring medical debt for collections.

Two posters presented at Kidney Week 2023 evaluated the global state of chronic kidney disease (CKD) and shed light on delays in CKD diagnoses in the United States.

Presenters at the American Society of Nephrology's Kidney Week 2023 discussed the past, present, and future of pediatric chronic kidney disease, as well as explored the obstacles and solutions for effective trial designs.